The Roles of Exosomal Circ-LRBA and 451/CRTC2 Signaling Axis in Colorectal Cancer
The Roles and Molecular Mechanism of Exosomal Circ-LRBA That Regulates miR-451/CRTC2 Signaling Axis in Colorectal Cancer Progression
1 other identifier
observational
200
1 country
1
Brief Summary
Colorectal cancer (CRC) is one of the most common malignant tumors in the world. Most of the patients with colorectal cancer were diagnosed in poor stage. Although 40% to 50% patients of colorectal cancer can be cured by surgery, but most patients have undergent metastasis or recurrence, and eventually death. In recent years, molecular targeted therapy has shown significant efficacy in specific patients. It was necessary to detect the corresponding molecular targets of tumors before selecting appropriate targeted drugs in clinic. The changing state of related gene molecules in colorectal cancer played a key role in drug selection, there were few effective targets so far. At present, metastasis and recurrence still be the most difficult problems in treatment. Therefore, investigators should deeply study the occurrence and development of colorectal cancer at the gene level and look for new biomarkers to predict the prognosis. Furthermore, the study can clarify the exact molecular mechanism of colorectal cancer. These will be important clinical significance for targeted therapy of colorectal cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2023
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 9, 2022
CompletedFirst Posted
Study publicly available on registry
October 13, 2022
CompletedStudy Start
First participant enrolled
January 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
ExpectedOctober 13, 2022
October 1, 2022
2.5 years
October 9, 2022
October 11, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
expressional quantity
Expression of CRTC2 in patient samples
Through study completion, an average of 2 year
Study Arms (2)
cancer group
control group
Interventions
Eligibility Criteria
1
You may qualify if:
- years old.
- \< BMI \< 27.9.
- \. The surgical methods are radical resection of rectal cancer, resection of right colon cancer, resection of left colon cancer and radical resection of sigmoid colon cancer.
You may not qualify if:
- Those who refuse to collect samples.
- Patients with severe dysfunction of coagulation, hepatorenal dysfunction or severe cardiopulmonary diseases.
- Patients who has a history of neoadjuvant radiotherapy or chemotherapy.
- Combining with distant multiple metastases of tumor
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Jingbo Chenlead
Study Sites (1)
The First Affiliated Hospital of Shandong First Medical University
Jinan, Lixia, 250014, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
October 9, 2022
First Posted
October 13, 2022
Study Start
January 1, 2023
Primary Completion
June 30, 2025
Study Completion (Estimated)
December 31, 2026
Last Updated
October 13, 2022
Record last verified: 2022-10
Data Sharing
- IPD Sharing
- Will share